Extent of Enhancement on Multiphase Contrast-enhanced CT Images is a Potential Prognostic Factor of Stage I-III Colon Cancer

Overview

Journal Eur Radiol

Specialty Radiology

Date 2018 Sep 27

PMID 30255251

Citations 6

Authors

Zhanhuai Wang

Yao Ye

Yeting Hu

Shugao Han

Lifeng Sun

Dong Xu

Kefeng Ding

Affiliations

Soon will be listed here.

Abstract

Objective: By evaluating extent of tumour enhancement on preoperative contrast-enhanced MDCT, we aimed to establish an imaging-based model to predict cancer-specific survival in stage I-III colon cancer.

Methods: A total of 548 stage I-III colon cancer patients who underwent curative resection from 2007 to 2013 were retrospectively included and divided into primary cohort and validation cohort according to admission time. The attenuation coefficient of each colon cancer was measured on the workstation by drawing the ROI in CT images. The enhancement ratio was calculated using maximum tumour attenuation value in triphasic MDCT scanning divided by the minimum. Patients were divided into low/high-enhancement groups according to the optimal cut-off value derived from time-dependent ROC curve. Kaplan-Meier method and COX regression analysis were adopted to evaluate prognostic value of variables. A nomogram for prognosis was conducted on the basis of a multivariate Cox proportional hazard model.

Results: No significant differences were observed in age, sex, pTNM stage, perioperative chemoradiotherapy, serum CEA, tumour size, tumour localisation and histologic type between low- and high-enhancement groups. The high-enhancement group had a significantly shorter cancer-specific survival rate (69.5%) than the low-enhancement group (85.9%) (p < 0.001). Subgroup analysis indicated that high-enhancement state was closely associated with increased risk of colon cancer mortality in stage I (p = 0.033), stage II (p = 0.002) and stage III (p = 0.014). Cox regression analysis indicated the extent of enhancement was an independent prognostic factor (HR 2.258, 95% CI 1.476-3.455; p < 0.001).

Conclusions: The extent of tumour enhancement on MDCT can serve as a potential risk factor for stage I-III colon cancer.

Key Points: • Survival rates of stage I-III colon cancer vary widely even within the same stage. • Prognostic value of the extent of tumour enhancement on MDCT was assessed. • The high-enhancement group had a significantly shorter cancer-specific survival rate.

Citing Articles

Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib.

Zhang J, Zhu H, Shen L, Li J, Zhang X, Bai C Chin J Cancer Res. 2023; 35(5):526-535.

PMID: 37969958 PMC: 10643338. DOI: 10.21147/j.issn.1000-9604.2023.05.09.

A prognostic nomogram for predicting recurrence-free survival of stage I-III colon cancer based on immune-infiltrating Treg-related genes.

Xu L, Liu M, Lian J, Li E, Dongmin C, Li X J Cancer Res Clin Oncol. 2023; 149(15):13523-13543.

PMID: 37498396 PMC: 10590341. DOI: 10.1007/s00432-023-05187-y.

18F-FDG PET/CT Image Deep Learning Predicts Colon Cancer Survival.

Tian M, Li Y, Chen H Contrast Media Mol Imaging. 2023; 2023:2986379.

PMID: 37181405 PMC: 10175011. DOI: 10.1155/2023/2986379.

Effects of Nutritious Meal Combined with Online Publicity and Education on Postoperative Nutrition and Psychological State in Patients with Low Rectal Cancer After Colostomy.

Qu L, Zhou M, Yu Y, Li K Comput Math Methods Med. 2022; 2022:1541385.

PMID: 35799641 PMC: 9256354. DOI: 10.1155/2022/1541385.

Tumor size measured by multidetector CT in resectable colon cancer: correlation with regional lymph node metastasis and N stage.

Mou A, Li H, Chen X, Fan Y, Pu H World J Surg Oncol. 2021; 19(1):179.

PMID: 34134714 PMC: 8210336. DOI: 10.1186/s12957-021-02292-5.

References

Miles K . Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol. 1999; 30(3):198-205. DOI: 10.1016/s0720-048x(99)00012-1. View

Altman D, Royston P . What do we mean by validating a prognostic model?. Stat Med. 2000; 19(4):453-73. DOI: 10.1002/(sici)1097-0258(20000229)19:4<453::aid-sim350>3.0.co;2-5. View

Gill S, Loprinzi C, Sargent D, Thome S, Alberts S, Haller D . Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol. 2004; 22(10):1797-806. DOI: 10.1200/JCO.2004.09.059. View

Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350(23):2343-51. DOI: 10.1056/NEJMoa032709. View

Choi H, Charnsangavej C, Faria S, Macapinlac H, Burgess M, Patel S . Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25(13):1753-9. DOI: 10.1200/JCO.2006.07.3049. View

Goh V, Halligan S, Wellsted D, Bartram C . Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study. Eur Radiol. 2008; 19(1):79-89. DOI: 10.1007/s00330-008-1128-1. View

Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J . Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011; 29(10):1261-70. DOI: 10.1200/JCO.2010.30.1366. View

Bertagnolli M, Redston M, Compton C, Niedzwiecki D, Mayer R, Goldberg R . Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol. 2011; 29(23):3153-62. PMC: 3157981. DOI: 10.1200/JCO.2010.33.0092. View

Benson 3rd A, Hamilton S . Path toward prognostication and prediction: an evolving matrix. J Clin Oncol. 2011; 29(35):4599-601. DOI: 10.1200/JCO.2011.37.8646. View

10.

Mols F, Beijers T, Lemmens V, van den Hurk C, Vreugdenhil G, van de Poll-Franse L . Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013; 31(21):2699-707. DOI: 10.1200/JCO.2013.49.1514. View

11.

Komori M, Asayama Y, Fujita N, Hiraka K, Tsurumaru D, Kakeji Y . Extent of arterial tumor enhancement measured with preoperative MDCT gastrography is a prognostic factor in advanced gastric cancer after curative resection. AJR Am J Roentgenol. 2013; 201(2):W253-61. DOI: 10.2214/AJR.12.9206. View

12.

Salvaggio G, Furlan A, Agnello F, Cabibbo G, Marin D, Giannitrapani L . Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. Radiol Med. 2013; 119(4):215-21. DOI: 10.1007/s11547-013-0332-5. View

13.

Ginat D, Gupta R . Advances in computed tomography imaging technology. Annu Rev Biomed Eng. 2014; 16:431-53. DOI: 10.1146/annurev-bioeng-121813-113601. View

14.

Zhu Y, Wang X, Zhang J, Chen Y, Kong W, Huang Y . Low enhancement on multiphase contrast-enhanced CT images: an independent predictor of the presence of high tumor grade of clear cell renal cell carcinoma. AJR Am J Roentgenol. 2014; 203(3):W295-300. DOI: 10.2214/AJR.13.12297. View

15.

Wang S, Sun Y, Liu Y, Zhou Y, Liu Y . CT contrast enhancement correlates with pathological grade and microvessel density of pancreatic cancer tissues. Int J Clin Exp Pathol. 2015; 8(5):5443-9. PMC: 4503119. View

16.

Naqvi J, Hosmane S, Lapsia S . Revisiting the potential signs of colorectal cancer on contrast-enhanced computed tomography without bowel preparation. Abdom Imaging. 2015; 40(8):2993-3001. DOI: 10.1007/s00261-015-0505-x. View

17.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

18.

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

19.

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

20.

Sobrero A, Grothey A, Iveson T, Labianca R, Yoshino T, Taieb J . The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?. Ann Oncol. 2018; 29(5):1099-1107. PMC: 6864492. DOI: 10.1093/annonc/mdy064. View